Engineered immune cells take on lupus and vasculitis in early trial
NCT ID NCT06294236
First seen Dec 18, 2025 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This early-stage study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to other therapies. SC291 uses specially designed immune cells from a donor to target and destroy faulty immune cells causing the disease. The main goal is to check safety, but researchers will also look for signs that the treatment is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Swedish Medical Center
Seattle, Washington, 98122, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.